Theravectys S.A.
http://www.theravectys.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Theravectys S.A.
Finance Watch: Two New VC Funds Target Early Stage And Beyond
Private Company Edition: venBio’s new fund plus Ysios Capital’s recent €216m ($260m) fund adds up to $810m in fresh venture capital for life science companies. Also, Nikang and Esco attracted $200m each in VC investment, Pulmocide closed a $92m series C round and Stablix launched with $63m.
Finance Watch: $2.2bn In New Funding Sources In February, So Far
Private Company Edition: New capital for health care and life science innovations include a fund for royalty deals, additional anti-infective funding, early-stage money and public health-focused cash. Also, Day One reveals a $130m series B venture round and Notch closes an $85m series A round.
Company Information
- Industry
-
Pharmaceuticals
- Drug Delivery
- Vaccines
-
Biotechnology
- Gene Therapy, Cell Therapy
-
Drug Discovery Tools
- Genomics-Proteomics